Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 3/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30803371 | 1.00 | ESR2 (0.46) | ESR2GRM5ADORA1NR1H2USP2 | |
| SCHEMBL14954612 | 1.00 | ESR2 (0.46) | ESR2GRM5ADORA1NR1H2USP2 | |
| SCHEMBL19331833 | 0.92 | MEN1 (0.42) | ESR2GRM5ADORA1NR1H2USP2 | |
| SCHEMBL21044819 | 0.92 | MEN1 (0.42) | ESR2GRM5ADORA1NR1H2USP2 | |
| SCHEMBL19331872 | 0.92 | MEN1 (0.42) | ESR2GRM5ADORA1NR1H2USP2 | |
| SCHEMBL99227 | 0.91 | GRM5 (0.53) | ESR2GRM5ADORA1NR1H2USP2 | |
| SCHEMBL344121 | 0.88 | USP2 (0.41) | ESR2GRM5NR1H2USP2SMN1; SMN2 | |
| SCHEMBL20660282 | 0.86 | GRM5 (0.49) | ESR2GRM5ADORA1NR1H2USP2 | |
| SCHEMBL20660281 | 0.86 | GRM5 (0.49) | ESR2GRM5ADORA1NR1H2USP2 | |
| SCHEMBL16493969 | 0.85 | ESR2 (0.46) | ESR2GRM5ADORA1NR1H2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116018138-A | Substituted 1H-imidazo [1,2-b ] pyrazole-3-carboxamides as inhibitors of brunauer tyrosine kinase | 河南知微生物医药有限公司 | 2023-04-25 | — | — | CN | disclosed |
| EP-2558468-B1 | 5, 7-SUBSTITUTED-IMIDAZO [1,2-C] PYRIMIDINES AS INHIBITORS OF JAK KINASES | ARRAY BIOPHARMA INC (US) | 2015-04-01 | — | — | EP | disclosed |
| US-8962596-B2 | 5,7-substituted-imidazo[1,2-C]pyrimidines as inhibitors of JAK kinases | ARRAY BIOPHARMA INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20130131039-A1 | 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES | ARRAY BIOPHARMA INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2558468-A1 | 5, 7-SUBSTITUTED-IMIDAZO [1, 2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES | Array Biopharma, Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011130146-A1 | 5, 7-SUBSTITUTED-IMIDAZO [1, 2-C] PYRIMIDINES AS INHIBITORS OF JAK KINASES | ARRAY BIOPHARMA INC. (US) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131039-A1 | 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES | JAK1, JAK3, JAK2 | ESR2 2919/4885GRM5 1974/4885ADORA1 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.